Quick Answer
Lantern Pharma Inc. reported Net Income Loss of -$17.12 million for the year ending 2025.
- Lantern Pharma Inc. showed an increase of +17.6% in Net Income Loss from 2024 to 2025.
- This data is from Lantern Pharma Inc.'s annual report (Form 10-K), filed with the SEC on March 30, 2026.
- XBRL data for this metric is available from 2019 to 2025 (7 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Over the full 7 years of available data (2019 to 2025), Lantern Pharma Inc.'s Net Income Loss has declined by 605.0%.
- Historical annual values: Fiscal year 2025: -$17.12 million | Fiscal year 2024: -$20.78 million | Fiscal year 2023: -$15.96 million | Fiscal year 2022: -$14.26 million | Fiscal year 2021: -$12.36 million | Fiscal year 2020: -$5.91 million | Fiscal year 2019: -$2.43 million.
- Data sourced from SEC EDGAR public filings as of June 21, 2026.
Last verified: